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Inappropriate use and overuse of antibiotics are among the most important factors in 
resistance development, and effective antibiotic stewardship measures are needed to 
optimize outcomes. Selection of appropriate antimicrobials relies on accurate and timely 
antimicrobial susceptibility testing. However, the availability of clinical breakpoints and 
in vitro susceptibility testing often lags behind regulatory approval by several years for new 
antimicrobials. A Working Group of clinical/medical microbiologists from Brazil, Canada, 
Mexico, Saudi Arabia, Russia and the UK recently examined issues surrounding antimicrobial 
susceptibility testing for novel antibiotics. While commercially available tests are being 
developed, potential surrogate antibiotics may be used as marker of susceptibility. Using 
tedizolid as an example of a new antibiotic, this special report makes recommendations to 
optimize routine susceptibility reporting.
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Widespread use and misuse of antibiotics have been associated with the selection and spread of 
antibiotic-resistant strains in both humans and animals. Antimicrobial resistance now poses a sig-
nificant threat to public health across the world, with alarming increases in the number of infections 
due to multidrug-resistant pathogens [1]. Consequently, availability of new antimicrobials is now a 
critical unmet need. In an effort to promote the development of new, more active antibiotics, the 
WHO recently published its first list of antibiotic-resistant ‘priority pathogens’ divided into three 
categories – critical, high and medium. It is hoped that the publication of this list will help guide 
research toward pathogens that present the greatest risks to public health [2].
While research on antibiotics to combat multidrug-resistant Gram-negative pathogens (e.g., car-
bapenem-resistant Enterobacteriaceae) is recognized as being a critical need, high priority is also given 
to Gram-positive bacteria, which remain a major cause of nosocomial infections [2,3]. Methicillin-
resistant Staphylococcus aureus (MRSA), in particular, is a prevalent threat in many parts of the world, 
and is often associated with significant morbidity and mortality, particularly in the elderly [4,5]. 
While vancomycin has been the mainstay of treatment for the management of MRSA infections [6], 
therapeutic failures have been reported for isolates possessing minimum inhibitory concentrations 
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(MICs) >1.5 μg/ml [7–9]. In addition, a load-
ing dose of vancomycin is recommended and 
therapeutic drug monitoring required to opti-
mize outcomes, so complicating clinical use [10], 
particularly in low-resource settings. The high 
activity of the novel oxazolidinone antibiotic 
tedizolid against Gram-positive bacteria, includ-
ing MRSA and vancomycin-resistant entero-
cocci, presents a new treatment option for these 
challenging pathogens, providing more potent 
activity than linezolid in vitro [11–14]. Although 
the optrA gene in some strains of Enterococci 
may confer elevated MICs to both tedizolid 
and linezolid [15–17], this mechanism has not 
yet been identified in MRSA. Noninferiority 
of tedizolid phosphate (given for 6 days) versus 
linezolid (10 days) has been demonstrated in two 
Phase III studies in patients with acute bacterial 
skin and skin s tructure infections [18,19].
Inappropriate use and overuse of antibiotics 
are among the most important factors in the 
development of resistance, and effective antibi-
otic stewardship measures are needed to opti-
mize the use of antimicrobials [20]. This includes 
use of restrictive reporting, and/or encouraging 
diverse prescribing to avoid overuse of valuable 
antibiotics and help control the increase in anti-
microbial resistance. Clinicians’ ability to select 
appropriate antimicrobials relies on accurate 
and timely antimicrobial susceptibility testing 
(AST), a process designed to predict clinical effi-
cacy [20]. However, performing effective AST 
is challenging, particularly for newly approved 
antibiotics, since availability of clinical break-
points and inclusion on commercial panels and/
or access to other in vitro susceptibility materials 
often lag behind regulatory approval by several 
years [1]. Obtaining sufficient clinical data to 
enable clinical breakpoints for new agents to 
be established is also problematic. A Working 
Group of clinical/medical microbiologists from 
Brazil, Canada, Mexico, Saudi Arabia, Russia 
and the UK was convened to examine issues sur-
rounding AST for novel antibiotics. This article 
summarizes their recommendations for optimal 
routine reporting of susceptibility to new anti-
biotics, using the novel oxazolidinone antibiotic 
tedizolid as an exemplar.
Overview of testing methodology
In recent years, few new Gram-positive directed 
antibiotics have become available, with only dal-
bavancin hydrochloride, oritavancin and tedi-
zolid phosphate being approved over the past 
5 years [21–26]. In order to select the optimal ther-
apy for their patients, clinicians must be aware of 
changes in resistance patterns and the effective-
ness of the antibiotics used to treat particular 
organisms over time. For this reason, a number 
of global antimicrobial surveillance programs, 
including STAR (Surveillance of Tedizolid 
Activity and Resistance; tedizolid), SOAR 
(Survey of Antibiotic Resistance; amoxicillin/
clavulanic acid, cefuroxime, cefaclor, azithro-
mycin and ofloxacin), ZAAPS (Zyvox® Annual 
Appraisal of Potency and Spectrum; linezolid) 
and TEST (Tigecycline Evaluation Surveillance 
Trial; tigecycline), have been initiated [27–31].
Susceptibility testing can be either auto-
mated (e.g., Vitek2, Microscan and Phoenix), 
or manual (e.g., disk diffusion [as recommended 
by the European Committee on Antimicrobial 
Susceptibility Testing – EUCAST – or Clinical 
and Laboratory Standards Institute – CLSI], 
broth microdilution or gradient testing 
[e.g., E-test®]). Each system has advantages and 
limitations, with some providing quality control 
ranges [1,32–35]. Working Group members report 
that the majority of laboratories in their countries 
use automated testing systems routinely for sus-
ceptibility testing, most of which provide MICs. 
Manual testing is frequently used to confirm 
automated AST results and/or MICs; E-test® 
and disk diffusion are the preferred methods, 
with the latter being the more favored choice in 
cost-conscious environments. Of note, in rou-
tine susceptibility testing, vancomycin MICs 
may not reflect accurately the actual MICs and 
their confirmation by E-test® has recently been 
recommended to minimize the risk of treatment 
failure [36]. Determination of MICs is important 
for certain strains not identified by an automated 
system or disk diffusion (e.g., vancomycin-inter-
mediate S. aureus [VISA]). Failure with empiric 
vancomycin treatment in a Saudi 69-year-old 
male patient, for example, prompted physicians 
to obtain more accurate susceptibility data on 
the pathogen isolated from blood. This led to the 
discovery of the first heterogeneous vancomycin-
intermediate Staphylococcus aureus (hVISA), a 
threatening signal to the effectiveness of empiric 
vancomycin treatment in hospitalized patients 
with severe infections [37].
Effective performance of AST by clinical 
microbiology laboratories is essential in order to 
determine susceptibility to the chosen empirical 
antimicrobial agents, and to detect the emer-
gence of resistance [38]. Use of susceptibility 
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breakpoints (e.g., those provided by the CLSI 
and EUCAST) is important, both for consistent 
reporting of antimicrobial susceptibility and for 
consistency and comparability of international 
surveillance schemes [39]. EUCAST and CLSI 
also advocate use of epidemiological cut-off 
Table 1. Antibiotics used as surrogate agents in clinical practice.
Surrogate 
agent
Pathogen Antibiotic(s) for which susceptibility is reported Ref.
Ampicillin Enterococci Amoxicillin-clavulanic acid, ampicillin-sulbactam, piperacillin, piperacillin-
tazobactam
[45]
Cefepime H. influenzae  Ceftaroline [46]
Cefoxitin Staphylococci Oxacillin [45]
    Cephalosporins† [47]
Ceftazidime H. influenzae Ceftaroline [46]
Ceftriaxone S. pneumoniae Ceftaroline [46]
  H. influenzae Ceftaroline [46]
Cephalothin Enterobacteriaceae Cefapirin, cephradine, cefaclor, cefadroxil, cefpodoxime, cephalexin and loracarbef [45,48]
Ertapenem Enterobacteriaceae 
Haemophilus spp. 
S. pneumoniae
Doripenem [49]
Erythromycin Streptococci Azithromycin, clarithromycin and dirithromycin [45]
Imipenem S. aureus Ceftaroline [46]
  P. aeruginosa Doripenem [50]
Levofloxacin S. pneumoniae Fluoroquinolones [51]
Linezolid Staphylococci 
Enterococci 
Streptococci 
Streptococcus anginosus group
Tedizolid [42]
  Staphylococci 
Streptococci
  [47]
Meropenem S. aureus Ceftaroline [46]
  P. aeruginosa Doripenem [50]
Nalidixic acid H. influenzae 
M. catarrhalis
Ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin [47]
Norfloxacin Staphylococci 
Streptococci
Ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin [47]
Oxacillin S. aureus Cefazolin, ceftriaxone, ceftaroline and nafcillin [52]
Penicillin Enterococci Ampicillin, amoxicillin, amoxicillin-clavulanic acid, ampicillin-sulbactam, 
piperacillin, piperacillin-tazobactam
[45]
Teicoplanin Staphylococci 
Streptococci
Dalbavancin [53]
Tetracycline Vibrio cholerae Doxycycline‡ [45]
  Staphylococci 
Streptococci 
H. influenzae 
M. catarrhalis 
N. gonorrhoeae
Doxycycline and minocycline [47]
Vancomycin Staphylococci 
Streptococci
Dalbavancin [53,54]
  Staphylococci 
Streptococci
Dalbavancin and oritavancin [47]
  Staphylococci 
Streptococci 
Enterococci
Oritavancin [55]
†Not cefixime, ceftazidime, ceftibuten and ceftolozane-tazobactam.
‡Disk diffusion should not be used for doxycycline due to poor correlation with minimum inhibitory concentration results.
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values as one of several tools in the process of 
establishing clinical breakpoints; determina-
tion of such cut-off values may promote more 
susceptibility testing and allow MIC values to 
be put into context [40]. While most laboratories 
follow either CLSI or EUCAST breakpoints for 
susceptibility testing, some may use both if a 
pathogen is not included in the guidelines they 
normally follow. When there is no available 
information on appropriate clinical breakpoints 
for certain bacteria, physicians may rely on their 
best judgment with regard to MIC findings 
and experience in eradicating those pathogens, 
and/or on consultation with clinical/medical 
m icrobiologists or infectious disease specialists.
Most laboratories in the Working Group 
members’ countries report an isolate’s suscep-
tibility to be ‘susceptible’, ‘resistant’ or ‘inter-
mediate’ according to either CLSI or EUCAST 
criteria. The ‘intermediate’ category has been 
used in a number of various ways, for example as 
a buffer to prevent very major and major errors, 
to be used alongside the ‘resistant’ category to 
indicate results that are ‘nonsusceptible’ and to 
indicate pathogen or drug combinations where 
an increased drug exposure may be necessary for 
optimal results [40]. However, antibiotic deci-
sion-making is usually based on ‘susceptible’ or 
‘resistant’ categories, since treatment choices for 
‘intermediate’ susceptibility are not clear-cut. 
‘Intermediate’ should be interpreted as ‘nonsus-
ceptible’ and physicians should thus choose an 
alternative antibiotic to which the pathogen is 
susceptible. Nevertheless, reporting susceptibil-
ity as ‘intermediate’ can be useful in some cases, 
for example if two antibiotics are used syner-
gistically (e.g., meropenem and colistin) or to 
optimize the antimicrobial dosage regimen [41].
Selection of antibiotics for routine susceptibil-
ity testing depends primarily on the type of AST 
method, particularly if an automated panel is 
used. All antibiotics included on the panel are 
routinely tested, although not all of those tested 
may be reported; reports are usually issued only 
for first-line antibiotics. Until the cause of an 
infection is known, initial therapy is generally 
empiric and guided by clinical presentation [20]. 
Clinical/medical microbiologists and infec-
tious disease specialists have an important role 
in advising physicians on the most appropriate 
antibiotics to use, although decision-making 
can also involve infectious disease specialists 
and clinical pharmacologists. The number and 
selection of antimicrobials tested is dependent 
on the organism isolated, infection site, the insti-
tution’s formulary, physician requests and the 
automated panel or other testing methodology 
used [38]. Notably, the choice of antibiotics to be 
tested via automated methods can be limited, 
including for new antibiotics that have yet to be 
adopted by automated systems. While inclusion 
of an antibiotic on the hospital formulary is a 
key factor in selection for susceptibility testing, 
availability on the automated panel, supply of 
the manual testing equipment (disks or gradi-
ent strips) and requests from physicians are also 
important.
The inclusion of new antibiotics on com-
mercial, automated test panels is often delayed 
for a considerable time after approval [38,42]. 
However, agents from the same class with simi-
lar activities can be used as surrogate markers 
(i.e., class representatives) to predict susceptibil-
ity of clinical isolates to new agents and/or to 
those not included in routine testing. Clinical 
laboratories have used surrogate testing success-
fully for decades (see Table 1). Reliability of a 
surrogate marker is typically analyzed by testing 
the categorical agreement between the suscepti-
bility results for the two agents, defining errors 
as very major (i.e., false-susceptibility), major 
(i.e., false-resistance) or minor (i.e., the result for 
one agent was intermediate while the other agent 
was susceptible, nonsusceptible or resistant) [43]. 
However, it should be noted that the chance of 
a very major error is extremely low when the 
occurrence of resistant isolates is rare or absent. 
Furthermore, in rare cases, susceptibility to a 
surrogate antibiotic might not reveal resistance 
to the agent in question, for example a recently 
recognized, uncommon variant of fexA confer-
ring resistance to florfenicol, but not to chloram-
phenicol [44]. Such reports highlight the need 
to review the utility of surrogate s usceptibility 
testing as new data emerge.
Testing of new antibiotics: a focus on 
tedizolid
An alternative approach to susceptibility testing 
is needed for new antibiotics as their inclusion 
on commercial AST panels is often delayed for 
several years after approval, which complicates 
testing and reporting [1]. Despite inclusion on 
hospital formulary, the use of new antibiotics 
may be restricted for some months, which limits 
the opportunity for physicians to gain clinical 
experience. This may be difficult to explain to 
physicians if the antibiotic is already included in 
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clinical practice guidelines. Consequently, clini-
cal/medical microbiologists have a responsibility 
to provide clinically relevant information to phy-
sicians and explain why it is or is not appropri-
ate to use an antibiotic. Additional barriers to 
susceptibility testing of new antibiotics include: 
problems with the availability and regular sup-
ply of materials required for manual testing; not 
being included on the hospital formulary; lack 
of breakpoints for certain pathogens; and the 
increased workload and costs associated with 
supplementary testing. Working Group mem-
bers report that novel antibiotics will most likely 
be routinely tested once they become available 
on an automated panel(s). Until then, suscepti-
bility testing for new agents is performed manu-
ally, but often undertaken only upon physician 
request. In the short term, surrogate agents 
(that are included on automated panels) can be 
used to predict pathogen susceptibility to new 
antibiotics [1].
Several methods are currently available to 
test tedizolid susceptibility, including the use 
of linezolid as a surrogate antibiotic. Linezolid 
susceptibility is considered a highly reliable sur-
rogate for tedizolid susceptibility; a high cat-
egorical agreement has been reported between 
the susceptibility of tedizolid and linezolid; and 
the very major error rates were low (≤0.2%) for 
all organisms tested [42]. Based on these findings, 
EUCAST recommends that isolates susceptible 
to linezolid can be reported as susceptible to 
tedizolid [47]. For isolates intermediate/resistant 
to linezolid, an MIC test must be performed to 
confirm susceptibility or resistance to tedizolid. 
Most laboratories in Working Group members’ 
countries would add to the AST report a ‘tedi-
zolid susceptible’ result based on a surrogate 
‘linezolid-susceptible’ actual testing result, but 
would not report a ‘tedizolid-resistance’ result 
without knowledge of the results of actual 
tedizolid susceptibility testing. AST results 
are typically discussed with the treating physi-
cian before reporting so as not to delay clini-
cal decision-making. The CLSI recommends 
that tedizolid and linezolid are included in the 
Group B optional primary test and reported 
selectively [45]. Additional methods available 
for tedizolid susceptibility testing include MIC 
test strips (Liofilchem s.r.l., Roseto, Italy) and 
a broth microdilution device (Sensititre™, 
Thermo Fisher Scientif ic Inc., OH, USA) 
developed primarily for research purposes [56]. 
Use of 20 μg disk diffusion has been approved 
by the CLSI for measurement of tedizolid sus-
ceptibility as a quality control measure [45]. To 
obtain susceptibility results in microbiology 
laboratories, currently a more practicable 2 μg 
disk diffusion method is under development, 
in addition to automated susceptibility testing 
panels. It should be noted that methodological 
testing issues have been observed with tedizolid 
and linezolid which suggest that 80% inhibition 
MIC end point criterion should be employed for 
testing both agents [57].
Tedizolid has demonstrated more potent 
activity in vitro than linezolid against Gram-
positive bacteria, including MRSA and vanco-
mycin-resistant enterococci, as well as noninfe-
riority in patients with skin and skin structure 
infections [11–14,18–19]. Of note, tedizolid retains 
in vitro activity against S. aureus and other 
Gram-positive bacterial strains that harbor 
the cfr-gene encoded methylase enzyme [58,59]. 
This methylase enzyme confers resistance 
against five structurally different antibiotic 
classes (e.g., clindamycin in the lincosamide 
class, chloramphenicol in the phenicol class, 
and linezolid, but not tedizolid, in the oxazoli-
dinone class) [58]. The encoded enzyme meth-
ylates the A2053 nucleotide in the peptidyl-
transferase center of the 23S ribosomal RNA, 
which is a very highly conserved site, and this 
methylation prevents binding of antibiotics to 
peptidyl-transferase center [60]. Importantly, 
chromosomal mutations in Domain V of rRNA 
or ribosomal L3 protein identified to date were 
demonstrated to confer resistance to both lin-
ezolid and tedizolid, stressing the need to test 
tedizolid susceptibility [59,61]. The Working 
Group stresses the importance of providing 
tedizolid susceptibility results in order to guide 
clinicians in selecting the most effective agent 
for their patients, and to provide an alternative 
option in cases of resistance development. They 
recommend the adoption of EUCAST guide-
lines on use of linezolid as a surrogate to predict 
tedizolid susceptibility [47], in order to enable 
routine inclusion of tedizolid in AST reports by 
microbiology laboratories. The Working Group 
also advocates having tedizolid MIC test strips 
in place in laboratories so that it is possible to 
perform tedizolid susceptibility testing, par-
ticularly when nonsusceptibility to linezolid 
is detected. Furthermore, they highlight the 
importance of a surveillance program for moni-
toring resistance and appropriate antibiotic use 
of all new antibiotics.
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Figure 1. Recommended approach for routine reporting of susceptibility of new antibiotics, for example, tedizolid. 
†Use of broth microdilution is also applicable. 
As recommended by published evidence/according to susceptibility testing guidance [42,47]. 
NS: Nonsusceptible; S: Susceptible.
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Conclusion & recommendations
The Working Group has highlighted the dif-
ficulty in acquiring sufficient clinical data to 
enable clinical breakpoints for new antibiotics 
to be established and the time taken (possibly 
up to 5 years) for such agents to be included in 
automated testing panels, which are often used 
for routine susceptibility testing. Policy makers 
should aim to minimize delays in the adoption 
of new breakpoints for antibiotics against emerg-
ing pathogens, particularly when containment of 
spread is vital; delays should be reduced to less 
than 1.5 years whenever possible [62]. However, 
to guide clinicians on appropriate treatment, it is 
critical that the susceptibility of new antibiotics 
is reported. Using tedizolid as an example, if it 
is not possible to determine susceptibility, data 
may be extrapolated by using linezolid as a sur-
rogate, allowing subsequent appropriate use of 
tedizolid. In situations identified by a clinical/
medical microbiologist (e.g., linezolid nonsus-
ceptible strains of Gram-positive bacteria) an 
appropriate manual test for tedizolid will be 
necessary (Figure 1). Susceptibility testing and 
routine reporting of selected new antibiotics can 
be desirable to ensure that clinicians make the 
appropriate choices for the management of infec-
tion, and that development of resistance is closely 
monitored as new agents become available.
Future perspective
At present, there is a considerable time lag 
between approval of new antibiotics, avail-
ability of clinical breakpoints and inclusion on 
New antibiotic:
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antibiotic: linezolid
Linezolid
susceptible
Report linezolid
and tedizolid
susceptibility
Linezolid   
nonsusceptible
Recommend: 
use a tedizolid MIC
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Tedizolid
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Tedizolid  
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Report tedizolid
susceptible,
linezolid resistant
Report linezolid and tedizolid
resistant − send to Reference
Laboratory for conrmation of
unusual phenotype 
S NS
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commercial AST panels. It is hoped that closer 
coordination in the coming years between those 
involved in drug development and AST panels 
and regulatory authorities will shorten this delay, 
enabling routine testing of new agents at the 
time of approval. In the meantime, to ensure 
appropriate antibiotic choice, it is essential that 
laboratories use the available tools to enable 
them to report susceptibility of new antibiotics.
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EXEcUtiVE SUMMaRY
Background
 ●  A Working Group of clinical/medical microbiologists from Brazil, Canada, Mexico, Saudi Arabia, Russia and the UK has 
made recommendations for optimal routine testing and reporting of susceptibility to new antibiotics, using the novel 
oxazolidinone antibiotic tedizolid as an example.
Overview of testing methodology
 ●  Most laboratories use automated testing systems (e.g., Vitek2, Microscan and Phoenix) routinely for susceptibility 
testing, with manual testing (e.g., EUCAST or CLSI disk diffusion, broth microdilution or gradient testing [e.g., E-test®]) 
used to confirm the results and minimum inhibitory concentrations (MICs).
 ●  The inclusion of new antibiotics on commercial, automated test panels and/or the availability of susceptibility testing 
materials, are often delayed for a considerable time after approval; however, agents from the same class with similar 
activities can be used as surrogate markers to predict susceptibility of clinical isolates to new agents and/or to those 
not included in routine testing.
Testing of new antibiotics: a focus on tedizolid
 ●  Several methods are currently available to test tedizolid susceptibility: use of linezolid as a surrogate antibiotic, MIC 
test strips (Liofilchem s.r.l.) and a broth microdilution device (Sensititre™, Thermo Fisher Scientific Inc.).
 ●  Adoption of EUCAST guidelines on use of linezolid as a surrogate to predict tedizolid susceptibility is recommended 
in order to enable routine inclusion of tedizolid in antimicrobial susceptibility testing reports; having tedizolid MIC 
test strips in place in laboratories is also advocated so that tedizolid susceptibility testing can be performed when 
nonsusceptibility to linezolid is detected.
Conclusion & recommendations
 ●  It can take up to 5 years for new antibiotics to be included in automated testing panels yet it is critical that the 
susceptibility of these agents is reported.
 ●  If it is not possible to determine susceptibility, data may be extrapolated by using a surrogate, for example, linezolid 
susceptibility as a reliable surrogate for tedizolid.
 ●  Susceptibility testing and routine reporting of selected new antibiotics is desirable to ensure that clinicians make the 
appropriate choices for the management of infection.
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